Results 161 to 170 of about 178,854 (310)

Association of nucleoside reverse transcriptase inhibitor use with reduced risk of Alzheimer's disease risk. [PDF]

Alzheimers Dement
Magagnoli J, Ambati M, Cummings TH, Nguyen J, Thomas CC, Ambati VL, Sutton SS, Gelfand BD, Ambati J.   +8 more
europepmc   +1 more source

Biological evaluation of inhibitors of reverse transcriptase from HIV type-1

, 2015
Hitendra Kumar Lautre, Taïbi Ben Hadda, Snigdha Das, Ajai K. Pillai   +3 more
openalex   +1 more source

New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains

, 2020
Marianna Nalli, Jorge I. Armijos Rivera, Domiziana Masci, Antonio Coluccia, Roger Badía, Eva Riveira‐Muñoz, A. Brambilla, Elisabetta Cinquina, Ombretta Turriziani, Francesca Falasca, Myriam Catalano, Cristina Limatola, José A. Esté, Giovanni Maga, Romano Silvestri, Emmanuele Crespan, Giuseppe La Regina   +16 more
openalex   +1 more source

Pro‐ATO/Allicin Liposomes for Dual‐Pathway Targeting of p53‐Mutant Tumors

Advanced Science, EarlyView.
Schematic illustration of the “pro‐ATO”/allicin liposomal strategy. Liposomal encapsulation improves the stability and bioavailability of both agents while masking allicin's odor. Upon release in the tumor microenvironment, ATO reactivates structural p53 mutants, and allicin inhibits ATR signaling while releasing H2S, collectively inducing synthetic ...
Xiaoling Xu, WeiYi Cheng, Menghang Yang, Li He, WeiYe Ren, JingQuan Chen, LiTing He, Dandan Bao, Zhihong Zhu, Lixin Wang, Qinghua Yao, Ji‐Gang Piao   +11 more
wiley   +1 more source

Novel effects of reverse transcriptase inhibitor supplementation in skeletal muscle of old mice. [PDF]

Physiol Genomics
Osburn SC, Smith ME, Wahl D, LaRocca TJ.
europepmc   +1 more source

Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains. [PDF]

Antimicrob Agents Chemother, 2021
Cilento ME, Reeve AB, Michailidis E, Ilina TV, Nagy E, Mitsuya H, Parniak MA, Tedbury PR, Sarafianos SG.   +8 more
europepmc   +1 more source

Nucleoside Reverse Transcriptase Inhibitor [PDF]

, 2020
openaire   +1 more source

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

, 2016
Lawrence Mbuagbaw, Sara Mursleen, James Irlam, Alicen B. Spaulding, George W. Rutherford, Nandi Siegfried   +5 more
openalex   +1 more source

Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase [PDF]

, 2019
Ping Gao, Xiqiang Cheng, Lin Sun, Shu Song, Mar Álvarez, Joanna Luczkowiak, Christophe Pannecouque, Erik De Clercq, Luis Menéndez‐Arias, Peng Zhan, Xinyong Liu   +10 more
openalex   +1 more source

TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2

Advanced Science, EarlyView.
This study identifies the E3 ligase TRIM40 as a key driver of pathological cardiac hypertrophy. TRIM40 binds PKN2 via its B‐box domain and, through its C29‐dependent catalytic activity, mediates K63‐linked ubiquitination of PKN2. This modification enhances PKN2 phosphorylation at Ser815, thereby driving hypertrophy.
Risheng Zhao, Xiaoli Cui, Huizhu Du, Zhuoqun Wang, Chang Liu, Linxin Zhang, Jianing Qi, Di Yang, Hui Yu, Shuang Yan, Wei Liu, Haiming Sun, Mengyang Wang   +12 more
wiley   +1 more source